Medios AG, a leading provider of Specialty Pharma in Europe, has announced the appointment of Katrin Neuffer as Director Investor Relations & Communications, effective immediately. Neuffer, 49, brings around 20 years of experience in capital markets communications to her new role, where she will oversee communications with investors, analysts, the media, and the public. She succeeds Claudia Nickolaus, who has led the department and will now hand over leadership.
Neuffer holds a degree in business administration and has a distinguished career. From 2007 to 2018, she served as Head of Investor Relations & Corporate Communications at SDAX-listed Wacker Neuson SE, guiding the company from its IPO through its establishment as a consistently attractive investment. She also led the Strategy and Sustainability departments there. Subsequently, she headed an international 20-member team as Vice President Investor Relations & Corporate Communications and Marketing at the Exyte Group (formerly M+W Group), where she was responsible for preparing an IPO with a targeted market capitalization of more than EUR 2 billion. Since 2020, she has worked as an independent consultant, advising publicly listed companies on investor relations, IPO preparation, and crisis and restructuring communications.
Her appointment comes at a pivotal time for Medios, as the company looks to reposition itself in the capital markets. Thomas Meier, CEO of Medios AG, commented, “With Katrin Neuffer, we are gaining a proven capital markets expert who has guided publicly listed companies through decisive phases of development, from IPOs to strategic repositioning. Her experience will help us reposition Medios in the capital markets and intensify our dialogue with investors, analysts, and the media.” Meier also expressed gratitude to Claudia Nickolaus for her years of dedicated service, noting her role in building Medios' Investor Relations activities, from financial reporting and ESG communications to the company's first Capital Markets Day in 2022.
The announcement is significant for investors and the industry as Medios prepares for key events in the 2026 financial year. These include the Half-Year Financial Report on August 12, participation in the Berenberg and Goldman Sachs 15th German Corporate Conference in Munich from September 21 to 23, the Medios Capital Markets Day on September 28/29, and the Quarterly Statement as of September 30 on November 10. These events will provide opportunities for Neuffer to engage with the financial community and showcase Medios' strategy and performance.
Medios AG is Germany's first listed specialty pharmaceutical company, with shares listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index. The company operates in Germany, the Netherlands, Belgium, and Spain, supporting key partners in the supply chain with innovative solutions and intelligent services. Medios focuses on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices, and pharmaceutical companies. More information on individualized medicine can be found at app.medios.group/en/individualizedmedicine.
Neuffer's extensive experience in guiding companies through IPOs and strategic transformations is expected to be an asset as Medios seeks to enhance its visibility and attractiveness to investors. Her appointment underscores Medios' commitment to maintaining robust investor relations and transparent communication, which are crucial for building trust and supporting the company's growth objectives.
